howdy Joe......there's a lot going here mate, a point to...

howdy Joe......there's a lot going here mate, a point to consider.....
Both GSK and Novartis held extensive ph1 trials into 701 and 731 and elected
to proceed to ph2....Those GSK trials must have cost them a small fortune, given
the number of enrolments and the time taken before they proceeded to PH2 dosage
to me means they explored all options and avenues....anyway the outcome so far
for Immutep is we have received circa $10M milestone payments from them alone.
Immutep itself has barely scratched the surface re autoimmune disease as yet but
consider what their aim is in this dept in pre clinical research.....To stop the disease
before it starts rather than treat it once it rears it's ugly head....
Then there's" insight", well and truly at the exploratory stage but diversification none
the less.......We have a developing Research company with funds and iniative and
a novel product that has ticked all boxes so far......
Forget the SP, it will rectify itself IMO...Good times coming methinks...